Kay Connelly, MGA member and co-chair of the Ann Arbor Support Group, sent the following information to the MGA office on an FDA approved drug treatment for generalized myasthenia gravis. It is called Soliris and Kay received the information through mda.org.
We have some exciting news to share with you: The FDA has approved Soliris to treat adults with generalized myasthenia gravis.
Soliris is a terminal complement inhibitor that targets a part of the immune system called the complement system, which is responsible for helping antibodies clear damaged cells and potentially toxic microbes that could cause infections. In MG, antibodies whose job it is to target these toxic pathogens instead inappropriately recruit the complement system and target the space across which nerve fibers transmit signals to muscle fibers, called the neuromuscular junction (NMJ). Soliris is thought to work in MG by inhibiting the complement pathway to prevent destruction of the NMJ. Soliris is not a cure, but it may lessen the symptoms experienced by people living with generalized MG.
For more on this exciting news, read FDA: Soliris is Approved to Treat Generalized MG in the United States, and be sure to check back at mda.org for updates.
At the present time, Soliris is very expensive.